RPL22 and glioblastoma: RPL5-uL18 inactivation has been described in 34% of breast cancers, in 28% of melanomas, in 11% of glioblastomas and in 2% of childhood T-cell Acute Lymphoblastic Leukemia (T-ALL) [95,96], while RPL22-eL22 is mutated or is less expressed in several solid tumours (endometrial cancers, colorectal cancer, gastric cancer, breast carcinoma, and non-small cell lung carcinoma) [97,98,99,100].